EP Global Communications Inc fka EPGL

[H8ster]

EPGL TIMELINE w/Links For new people. This didn't happen overnight. We are now 8 months into this. It has taken time. from .001 to .006. This is not some 'overnight' sensation. This is real and its only going to get better as more time passes.

March 28th, 2012:
EP Global Communications, Inc. Reaches Agreement With Major Debt Holders to Restructure and Become Medical Device Manufacturer and Marketing Company.
Deal Reached!

April 19th, 2012
EP Global Communications, Inc. Announces Details on Restructuring Plans and Upcoming Shareholder Meeting
Details

June 27th, 2012
EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
Company Becomes Medical Device Manufacturer and Marketer
This is a MUST read

July 11th, 2012
EP Global Communications, Inc., Announces the Appointment of Corey W. Hunter M.D. as Company Medical Director and Chairman of Scientific Advisory Board. Respected Pain Physician Headed a Team of Scientists at NYU for Early Findings on the FDA Cleared MPDD Device. Will Now Lead Device to the U.S. and International Healthcare Markets.
All the toxic debt has now been eliminated and there will be no unscrupulous dumping of shares into the market as service to debt ever again. The restructuring partners will never consider such a financing arrangement in the future and will not allow that predicament to occur to the Company or its shareholders again. In contrast, the restructuring partners of the Company are committed to growing the Company and shareholder value significantly for the long term.
Corey Hunter, M.D. & Elimination of Toxic Debt

July 26th, 2012
EP Global Communications, Inc. Announces Friday July 27, 2012 as Effective Date for Approved Reverse Split
EP Global Communications, Inc., announces that FINRA has set Friday July 27, 2012 as the market effective date for the 10:1 reverse split of common outstanding shares. The Company shareholders previously approved the reverse split on June 8, 2012.
As a result, the Company will eliminate 100% of major debt and effectuate a new direction into the medical device manufacturing and marketing sector.
EPGL's Opening Day

August 21st, 2012
EPGL Launches Twitter account and begins to update shareholders regularly with tweets and Q&A sessions
Twitter @EPGLMed

August 30th, 2012
EP Global Communications, Inc., Announces First Orders for MPDD Medical Device and the Addition of Eric Lee M.D. M.A. to Medical Team
First Revenues and Addition of Eric Lee, M.D.

September 24th, 2012
EP Global Communications, Inc. Lands One of the World's Leading Biomedical Engineers.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. The worldwide market for Bio-MEMS medical technology is estimated to grow into hundreds of billions of dollars over the next several years in healthcare as well as other technological markets. The Company plans to aggressively pursue new technology opportunities in this field of medical technology.
EPGL hires David T. Markus Ph.D

September 26th, 2012
EPGL Launches Website
EPGL Website

October 9th, 2012
Ryan M. Stellar M.E. B.E. joins Corey Hunter M.D., Eric Lee, M.D.M.A. and David T. Markus Ph.D. on the EPGL Team.
EPGL Team

November 28th, 2012
EP Global Communications, Inc. Releases Dramatically Improved Balance Sheet After Restructuring, Announces New Assets
For the First Time in Two Years, Company Begins to Report Again and Move Up OTC Tiers on the Way to Full SEC Reporting in 2013
EPGL Begins Reporting. Sheds 'No Info Status'

November 28th, 2012
EPGL is announcing today for the first time, it has acquired significant new assets other than the MPDD device rights, in the BioMEMS arena. BioMEMS will be a major focus for the Company going forward as previously announced.
BioMEMS devices are as important to the future of medicine as microprocessors were to the computer revolution at the end of the last century. BioMEMS is a science that includes more than simply finding biomedical applications for microelectromechanical systems devices. It represents an expansion into a host of new polymer materials, microfluidic physics, surface chemistries and their modification, 'soft' fabrication techniques, biocompatibility, and cost-effective solutions to biomedical problems. It brings together the creative talents of electrical, mechanical, optical, and chemical engineers, materials specialists, clinical laboratory scientists, and physicians. BioMEMS devices are the platform upon which nanomedicine will be delivered.
EPGL Enters bioMEMS Arena